The aim is to “activate these guidelines in a way that they become more actionable for clinicians,” Harlan Krumholz says.

Treatment should be stopped if nonarteritic anterior ischemic optic neuropathy, which can cause vision loss, is diagnosed.

The lack of effect shouldn’t detract from MINT, which showed a strong trend toward benefit with liberal blood transfusion.